REVIEW article
Front. Med.
Sec. Regulatory Science
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1571922
Training and Practice for Drug Inspectors in China Training and Practice for Drug Inspectors in China: Experiences, Challenges, and Developments
Provisionally accepted
- 1China Pharmaceutical University, Nanjing, China
- 2Jinan Central Hospital, Jinan, Shandong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The professional level and inspection ability of drug inspectors directly determine the quality of inspection and affect drug safety. Drug inspectors need to guarantee that they can effectively perform their duties and better provide reliable supervision by receiving strict qualification authentication, systematic professional training, and standardized behavior management. This paper highlights the current situation of training and practice for drug inspectors in China, particularly the development and achievements in recent years, and examines the current challenges and opportunities facing the drug inspector training system in China and proposes some recommendations for improving the drug inspector training system, aiming to provide some insights for improving the overall quality and modernizing the inspection abilities of drug inspectors in China.
Keywords: China, drug regulation, Drug inspector, Practice, Present and future, training
Received: 06 Feb 2025; Accepted: 20 May 2025.
Copyright: © 2025 Sun, Guo, Shi, Wu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fang Wu, China Pharmaceutical University, Nanjing, China
Yongze Zhang, China Pharmaceutical University, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.